Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$35.35 - $50.67 $1.41 Million - $2.03 Million
-40,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $539,700 - $714,900
15,000 Added 60.0%
40,000 $1.47 Million
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $45,060 - $67,740
-1,000 Reduced 3.85%
25,000 $1.13 Million
Q1 2020

May 15, 2020

BUY
$40.01 - $73.97 $1.04 Million - $1.92 Million
26,000 New
26,000 $1.23 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Atlas Principals, LLC Portfolio

Follow Atlas Principals, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atlas Principals, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atlas Principals, LLC with notifications on news.